DAX drifts as equities slide

As the euro continues to strengthen against the US dollar, nerves are beginning to show in the predominantly export driven Germany 30.

Linde AG and Deutsche Bank AG lead the Germany 30 lower as European equity markets selloff across the board. Bayer has warranted most of the headlines after it completed the acquisition of Merck & Co’s consumer care business. This increases the pharmaceutical company’s exposure to the ‘over the counter’ drug business, just behind Johnson & Johnson in size.

Over the course of 2014 the Germany 30 has made a succession of lower highs because it has struggled to counter both global issues like the Ukraine situation, and a eurozone yet to fully convince that its recovery is fully under way. In contrast to this EUR/USD has continued to climb and has once again broken above the $1.39 level. The European Central Bank has stated that it is watching the strength of the euro, and has stopped just short of stating what action it will take should it rise too much. The increased strength of the euro has weakened the attractiveness of German exporters and subsequently stifled the Germany 30’s ability to head higher.

Until the euro begins to weaken against the US dollar we feel the Germany 30 will be prevented from rising higher much, and the precedent of lower highs could last.

Germany 30 chart

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.